Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
21.25
+0.05 (0.24%)
Apr 17, 2026, 10:35 AM CET
Market Cap853.96M +6.8%
Revenue (ttm)319.73M +313.8%
Net Income229.68M +407.1%
EPS5.70 +408.9%
Shares Out40.28M
PE Ratio3.72
Forward PE11.71
Dividendn/a
Ex-Dividend Daten/a
Volume2,904
Average Volume25,790
Open21.40
Previous Close21.20
Day's Range21.05 - 21.40
52-Week Range19.56 - 27.80
Beta0.01
RSI45.27
Earnings DateMar 27, 2026

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 201
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

In 2025, Philogen's revenue was 319.73 million, an increase of 313.81% compared to the previous year's 77.26 million. Earnings were 229.68 million, an increase of 407.10%.

Financial Statements